The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection
FDA 正在进行的一项噬菌体治疗慢性假体周围关节感染的 II/III 期临床研究中,磷壁酸糖基化在噬菌体活性和选择中的作用
基本信息
- 批准号:10704149
- 负责人:
- 金额:$ 41.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAntibioticsBacteriaBacterial InfectionsBacteriophagesBindingBiological AssayBioreactorsCase SeriesChronicClinicalClinical ResearchComplicationCulture MediaDataEffectivenessEnrollmentEnvironmentFDA approvedFailureFundingFutureGoalsGrowthGuidelinesHistologicImplantIn VitroKnowledgeLibrariesMalignant NeoplasmsMeasuresMethodsMicrobial BiofilmsOperative Surgical ProceduresOrganismOutcomePathway interactionsPatient IsolationPatientsPatternPeriprosthetic joint infectionPhasePhenotypePopulationProcessProtocols documentationReproducibilityRoleSafetySeriesSiteStaphylococcus aureusSurfaceSynovial FluidTeichoic AcidsTestingTherapeuticTissuesTreatment ProtocolsUnited StatesVariantVirusWorkboneglycosylationimprovedin vitro activityin vivoknee replacement arthroplastymortalitynovel strategiesnovel therapeutic interventionnovel therapeuticspeptidoglycan receptorreceptorscreeningsoft tissuesuccesstissue culture
项目摘要
PROJECT SUMMARY
The most common major surgical procedure in the United States is total knee arthroplasty. Periprosthetic joint
infection (PJI) is the most severe complication in total knee arthroplasty, and the largest reason for total knee
arthroplasty revision in approximately 25% of all revisions. The 5-year mortality for PJI is 20%, higher than most
cancers. Bacteriophage therapy is a promising therapy for chronic bacterial infections. Our group has completed
a series of phage therapies in recalcitrant chronic PJI cases under compassionate use guidelines with the FDA.
Based on its success, this is now an independently funded FDA Phase II/III study where enrollment has just
begun. These therapies utilize bacteriophages, viruses specific to bacteria, to bind and lyse the bacteria.
Preoperative bacterial cultures are obtained and screened against a large phage library to select a specific phage
matched to the clinical isolate. This method is similar to determining antibiotic sensitivity using CLSI protocols.
Matching a phage to an isolate is necessary as phages bind specific surface receptors that can have large
variations in the same bacterial species. In Staphylococcus aureus, the most common organism in PJI, phages
primarily bind to wall teichoic acid (WTA), a peptidoglycan receptor. WTA can have different glycosylation
dependent on the local environment and growth states of the bacteria. The objective of this proposal is to
determine how changes in WTA glycosylation vary under different environmental conditions and their resulting
impact on phage activity. This will contribute to our long-term goal to develop new treatment strategies for PJI.
The rationale for this work is that an improved understanding of changes in WTA glycosylation will allow accurate
phage selection to consequently create effective reproducible protocols to inform future clinical studies and
therapy.
项目总结
在美国最常见的主要外科手术是全膝关节置换术。假体周围关节
感染(PJI)是全膝关节置换术中最严重的并发症,也是导致全膝关节置换的最大原因。
关节置换翻修术占所有翻修术的约25%。PJI的5年死亡率为20%,高于大多数
癌症。噬菌体疗法是治疗慢性细菌感染的一种很有前途的疗法。我们小组已经完成了
根据FDA的同情性使用指南对顽固性慢性PJI病例进行的一系列噬菌体疗法。
基于其成功,这现在是一项独立资助的FDA第二/第三阶段研究,在该研究中,登记人数刚刚
开始了。这些疗法利用噬菌体--细菌特有的病毒--来结合和溶解细菌。
手术前获得细菌培养物,并与大噬菌体文库进行筛选,以选择特定的噬菌体
与临床分离株相匹配。这种方法类似于使用CLSI协议来确定抗生素敏感性。
将噬菌体与分离株进行匹配是必要的,因为噬菌体结合了特定的表面受体,这种受体可能具有
同一细菌种类的变异。在金黄色葡萄球菌中,PJI中最常见的有机体是噬菌体
主要与壁磷壁酸(WTA)结合,这是一种肽聚糖受体。WTA可以有不同的糖基化
取决于当地的环境和细菌的生长状态。这项建议的目的是
确定WTA糖基化在不同环境条件下的变化及其结果
对噬菌体活性的影响。这将有助于我们开发新的PJI治疗策略的长期目标。
这项工作的基本原理是,对WTA糖基化变化的更好理解将使准确
噬菌体选择,从而创建有效的可重复的方案,以通知未来的临床研究和
心理治疗。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The stability of Staphylococcal bacteriophages with commonly used prosthetic joint infection lavage solutions.
葡萄球菌噬菌体与常用假体关节感染灌洗液的稳定性。
- DOI:10.1002/jor.25731
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Doub,JamesB;Fogel,Jessa;Urish,KenL
- 通讯作者:Urish,KenL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James B. Doub其他文献
Bacterial Aggregation in Cerebral Spinal Fluid: The Extent it Occurs and the Clinical Ramifications
- DOI:
10.1007/s00284-024-03727-4 - 发表时间:
2024-06-04 - 期刊:
- 影响因子:2.600
- 作者:
Hamda Siddiqui;Gunjan Parikh;James B. Doub - 通讯作者:
James B. Doub
Do All Prosthetic Joint Infection Clinical Isolates Form Aggregates in Synovial Fluid That Are Resistant to Antibiotic Agents?
是否所有假体关节感染临床分离株都会在滑液中形成对抗生素具有耐药性的聚集体?
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:2
- 作者:
Hamda Siddiqui;Adam Jasiak;James B. Doub - 通讯作者:
James B. Doub
Evaluation of Intra-Operative Topical Vancomycin and the Incidence of Acute Kidney Injury.
术中局部使用万古霉素和急性肾损伤发生率的评估。
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:2
- 作者:
A. Blackman;Manjari Joshi;James B. Doub;H. Seung;Mary G. Banoub;K. Claeys;E. Heil - 通讯作者:
E. Heil
The Location of Biofilms on Chronic Prosthetic Joint Infections and the Ramifications for Clinical Practice
- DOI:
10.1016/j.artd.2023.101314 - 发表时间:
2024-02-01 - 期刊:
- 影响因子:
- 作者:
James B. Doub;David Parmiter;Christine A. Brantner;Matthew Moshyedi;Meghan Hughes;Matthew Kolevar;Aaron Johnson - 通讯作者:
Aaron Johnson
A rare case of Blastomyces dermatitidis brain abscess in an immunocompetent host
免疫功能正常宿主中罕见的皮炎芽生菌脑脓肿病例
- DOI:
10.1016/j.mmcr.2020.03.001 - 发表时间:
2020 - 期刊:
- 影响因子:2.2
- 作者:
Magdalena Slomka;James B. Doub - 通讯作者:
James B. Doub
James B. Doub的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James B. Doub', 18)}}的其他基金
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection
FDA 正在进行的一项噬菌体治疗慢性假体周围关节感染的 II/III 期临床研究中,磷壁酸糖基化在噬菌体活性和选择中的作用
- 批准号:
10598830 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别:
相似海外基金
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 41.55万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 41.55万 - 项目类别:
Research Grant
Hitting bacteria with a Bam: Lectin-Like Antimicrobials as New Antibiotics
用 Bam 击中细菌:凝集素类抗菌剂作为新型抗生素
- 批准号:
DP230102150 - 财政年份:2023
- 资助金额:
$ 41.55万 - 项目类别:
Discovery Projects
“L-form” bacteria: basic science, antibiotics, evolution and biotechnology
L 型细菌:基础科学、抗生素、进化和生物技术
- 批准号:
FL210100071 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别:
Australian Laureate Fellowships
Systematic identification of synthetic interactions in bacteria towards the next-generation of antibiotics
系统鉴定细菌与下一代抗生素的合成相互作用
- 批准号:
468567 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别:
Operating Grants
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10708102 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别:
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10587015 - 财政年份:2022
- 资助金额:
$ 41.55万 - 项目类别:
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
- 批准号:
10581945 - 财政年份:2021
- 资助金额:
$ 41.55万 - 项目类别:
Developing novel antibiotics from natural products against resistant bacteria
从天然产物中开发针对耐药细菌的新型抗生素
- 批准号:
2599490 - 财政年份:2021
- 资助金额:
$ 41.55万 - 项目类别:
Studentship
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
- 批准号:
10358855 - 财政年份:2021
- 资助金额:
$ 41.55万 - 项目类别:














{{item.name}}会员




